At present, many targets of MM CAR-T therapy are being studied, such as BCMA, kappa light chain, SLAMF7, GPRC5D, activated integrin β7, CD19, CD138, etc. (15). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.